These benefits, along with a preceding report showing that a little-molecule ACKR3 agonist CCX771 reveals anxiolytic-like conduct in mice,2 guidance the strategy of targeting ACKR3 as a novel approach to modulate the opioid method, which could open up new therapeutic avenues for opioid-relevant